Product Description
a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules that help cause disease, have been removed) when administered intravenously to participants with metastatic castration-resistant prostate cancer (mCRPC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02625857)
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Nondrug
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CR108224 | P2 |
Withdrawn |
Prostate Cancer |
2018-09-01 |
2019-03-20 |
Treatments |
|
| CR107668 | P1 |
Completed |
Prostate Cancer |
2018-07-03 |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|